Company Overview
American Healthcare U.S.-based business | International distribution relationships | Flexible transaction structures
American Healthcare Capital is pleased to present an investment or acquisition opportunity in an established U.S.-based supplier and distributor of proprietary, food-grade nutraceutical ingredients serving dietary supplement and skincare manufacturers. The business combines more than two decades of operating history with branded ingredients and long-standing domestic and international relationships.
Business and Investment Highlights
The portfolio spans collagen and botanical ingredients for joint health, healthy aging, cognitive wellness, antioxidant support, and beauty-from-within applications. The operating model combines external ingredient supply with in-house documentation, packaging, warehousing and fulfillment. An experienced team supports commercial relationships spanning approximately a decade or more; the owner is available for agreed transition and successor training.
Clinical Research and Intellectual Property
Management reports that approximately 90% of branded ingredients are supported by published human clinical studies, including randomized, double-blinded, placebo-controlled trials. Examples include a randomized, controlled study in approximately 50 healthy adults evaluating telomere health and cellular-aging markers, and a randomized, double-blinded, placebo-controlled trial in 90 male and female subjects evaluating cardiovascular outcomes with statistically significant benefits. Management also reports three issued patents protecting the marine-derived ingredient portfolio specifically for brain and cognitive health applications.
Financial Highlights
The Company generated approximately $2.47 million in sales and $912,000 in reported net income in FY 2024, followed by $2.57 million in sales and $753,000 in reported net income in FY 2025. For the eight months ended August 31, 2026, the Company reported approximately $1.18 million in sales and $300,000 in net income.
Management forecasts full-year sales of approximately $2.60 million in 2026 and $3.00 million in 2027.
Growth Opportunity
Growth priorities include broader adoption of established ingredients, commercialization of newer formulations, additional distributor and manufacturing relationships, and expansion into direct-to-consumer and retail channels under an agreed transaction scope. A strategic or capital partner could contribute distribution access, commercial resources, marketing capabilities, and working capital to accelerate these initiatives.
Asking Price and Valuation
The seller is open to a full acquisition you can say including licensing IP, majority sale or recapitalization with retained equity, minority growth investment, and other mutually acceptable structures. Valuation and the allocation between shareholder liquidity and new growth capital will be determined through discussion and negotiation. The seller has proposed retaining underlying intellectual property while granting exclusivity; the definitive commercial rights remain to be agreed, and any alternative IP arrangement requires seller agreement.